This is a demo store. No orders will be fulfilled.

Tralokinumab (anti-IL-13) - Primary antibody, specific to IL13, >95%, high purity, Human IgG4SP, INHIBITOR of Interleukin-13 inhibitor, INHIBITOR of Interleukin-13 inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human,Mouse
  • Isotype: Human IgG4SP
  • Conjugation: Unconjugated
In stock
Item Number
Ab170946
Grouped product items
SKU Size
Availability
Price Qty
Ab170946-100μg
100μg
10
$69.90
Ab170946-1mg
1mg
4
$339.90
Ab170946-5mg
5mg
1
$669.90
Ab170946-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,049.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Tralokinumab (anti-IL-13) - Primary antibody, specific to IL13, >95%, high purity, Human IgG4SP, INHIBITOR of Interleukin-13 inhibitor
Synonyms Allergic rhinitis antibody | ALRH antibody | BHR 1 antibody | BHR1 antibody | Bronchial hyperresponsiveness 1 (bronchial asthma) antibody | IL 13 antibody | IL-13 antibody | Il13 antibody | IL13_HUMAN antibody | Interleukin 13 antibody | Interleukin-13 an
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity IL13
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type INHIBITOR
Mechanism of action INHIBITOR of Interleukin-13 inhibitor
Product Description

Tralokinumab (anti-IL-13), a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab (anti-IL-13) can be used for the research of the atopic dermatitis (AD).
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Isotype Human IgG4SP
Light Chain Type lambdaC2
SDS-PAGE 27.8 kDa (Light Chain) & 51.7 kDa (Heavy Chain), under reducing conditions; 170.5 kDa, under non-reducing conditions.
Purification Method Protein A purified
Purity >95%
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 1044515-88-9

Associated Targets(Human)

IL13 Tclin Interleukin-13 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Tralokinumab (anti-IL-13) (Ab170946) - ELISA
Immobilized Tralokinumab (anti-IL-13) (Ab170946) at 2 μg/mL can bind human IL-13 protein with the EC₅₀ of 3.33 ng/mL.

Tralokinumab (anti-IL-13) (Ab170946) - SEC
The purity of Tralokinumab (anti-IL-13) (Ab170946) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number Certificate Type Date Item
ZJ24F0303732 Certificate of Analysis Mar 26, 2024 Ab170946
ZJ24F0303731 Certificate of Analysis Mar 26, 2024 Ab170946
ZJ24F0303730 Certificate of Analysis Mar 26, 2024 Ab170946

Alternative Products

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.